EBA, Safety and Tolerability of Sanfetrinem Cilexetil
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the 2-week bactericidal activity, pharmacokinetics, safety and tolerability of
sanfetrinem cilexetil in participants with rifampicin-susceptible pulmonary tuberculosis.
Phase:
Phase 2
Details
Lead Sponsor:
TASK Applied Science
Collaborators:
European and Developing Countries Clinical Trials Partnership (EDCTP) GlaxoSmithKline